Illumina enters its May 21 earnings call with an unusual setup: shorts are quietly exiting a stock that just posted a blowout quarter, while options traders are near the most defensive they've been all year. The tension between a rapidly rising share price and persistent hedging demand is the story of this week.
The most striking development is the short squeeze underway in the lending market. Short interest has dropped 10.4% over the past week to 4.3% of free float — roughly 6.5 million shares — and is down 13.6% over the past month. That's a meaningful retreat. Look back to early April and the picture is even starker: short interest was running near 7.8 million shares. The cover-and-exit has been sharp and orderly. Borrow costs reflect how little stress remains — cost to borrow is just 0.41%, down from above 0.55% six weeks ago. Availability in the lending pool is comfortable, with the ORTEX short score easing from 42.8 to 40.6 over the past week, well off any stress levels. The lending market is, in short, loose: there is no squeeze pressure and no borrow squeeze forming ahead of the next print.
Options positioning tells a different story. Put/call ratio has climbed to 0.59, nearly two standard deviations above its 20-day average of 0.54 — and just a whisker below its 52-week high of 0.593. That's the most defensive options positioning of the past year. The divergence is notable: short sellers are covering into strength, but options traders are stacking up protection. It points to a market that believes the near-term trade is higher, but wants insurance against a stumble at the May 21 report.
The Street is broadly cautious on valuation even as it acknowledges the fundamental improvement. Most of the analyst moves after last month's Q1 beat — the stock surged 12.8% on April 30 and is up 20.5% over the past month — saw firms lift targets while keeping non-bullish ratings. JPMorgan nudged its target to $125 from $120 but held at Neutral. Barclays raised to $122 from $110, remaining Underweight. Citigroup lifted its Sell target from $80 to $95. Evercore ISI, the one bullish voice, raised its Outperform target to $155 from $150. With the stock at $145.7 and the mean analyst target near $141, the consensus is now slightly below the current price — a configuration that limits upside unless the May 21 print delivers another positive surprise. The bull case centres on clinical consumables growth and raised EPS guidance to $4.45–$4.55 for the year. The bear case: instruments revenue is under pressure, Q3 guidance last year flagged a year-on-year revenue decline, and NovaSeq X shipments have been soft.
Institutional ownership gives one additional datapoint worth noting. Capital Research added 570,000 shares in the latest reporting period and is now the largest holder at 13.5%. BlackRock added 281,000 shares. Against that, Corvex Management — a hedge fund with board representation — has been a persistent seller this week: two Form 4 filings show sales of 88,804 shares between May 7 and May 11 worth roughly $12.7 million in aggregate. Corvex still holds approximately 3.8 million shares, so this is a trim rather than an exit, but the timing — selling into the post-earnings bounce — is worth tracking. The insider register beyond Corvex is quiet; executive sales back in February were routine plan-related disposals.
The last two earnings events reinforce how consequential the May 21 print could be. Q1 2026 (April 30) moved the stock 12.8% in a single session and 15.2% over the following week. The prior quarter moved 2.5% the next day. Illumina's earnings outcomes are volatile and directional — the bets are rarely small. With puts stacked near 52-week highs, options traders are pricing in that asymmetry even as short sellers clear out.
What to watch into May 21: whether the put/call ratio keeps climbing toward and beyond its 52-week high as the event approaches, whether Corvex's selling pace accelerates, and whether any bellwether firm breaks from the current holding-pattern consensus to make a more decisive call on valuation now that the stock has reclaimed $145.
See the live data behind this article on ORTEX.
Open ILMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
